289 related articles for article (PubMed ID: 30530621)
21. Expression of recombinant Clostridium difficile toxin A and B in Bacillus megaterium.
Yang G; Zhou B; Wang J; He X; Sun X; Nie W; Tzipori S; Feng H
BMC Microbiol; 2008 Nov; 8():192. PubMed ID: 18990232
[TBL] [Abstract][Full Text] [Related]
22. Total synthesis of Le(A)-LacNAc pentasaccharide as a ligand for Clostridium difficile toxin A.
Zhang P; Ng K; Ling CC
Org Biomol Chem; 2010 Jan; 8(1):128-36. PubMed ID: 20024143
[TBL] [Abstract][Full Text] [Related]
23. Human intestinal enteroids as a model of
Engevik MA; Danhof HA; Chang-Graham AL; Spinler JK; Engevik KA; Herrmann B; Endres BT; Garey KW; Hyser JM; Britton RA; Versalovic J
Am J Physiol Gastrointest Liver Physiol; 2020 May; 318(5):G870-G888. PubMed ID: 32223302
[No Abstract] [Full Text] [Related]
24. Cellular uptake of Clostridium difficile TcdA and truncated TcdA lacking the receptor binding domain.
Gerhard R; Frenzel E; Goy S; Olling A
J Med Microbiol; 2013 Sep; 62(Pt 9):1414-1422. PubMed ID: 23558138
[TBL] [Abstract][Full Text] [Related]
25. Clostridium difficile toxins: more than mere inhibitors of Rho proteins.
Genth H; Dreger SC; Huelsenbeck J; Just I
Int J Biochem Cell Biol; 2008; 40(4):592-7. PubMed ID: 18289919
[TBL] [Abstract][Full Text] [Related]
26. Use of a neutralizing antibody helps identify structural features critical for binding of
Kroh HK; Chandrasekaran R; Rosenthal K; Woods R; Jin X; Ohi MD; Nyborg AC; Rainey GJ; Warrener P; Spiller BW; Lacy DB
J Biol Chem; 2017 Sep; 292(35):14401-14412. PubMed ID: 28705932
[No Abstract] [Full Text] [Related]
27. Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models.
Tian JH; Glenn G; Flyer D; Zhou B; Liu Y; Sullivan E; Wu H; Cummings JF; Elllingsworth L; Smith G
Vaccine; 2017 Jul; 35(33):4079-4087. PubMed ID: 28669616
[TBL] [Abstract][Full Text] [Related]
28. Comparison of VIDAS CDAB and CDA immunoassay for the detection of Clostridium difficile in a tcdA- tcdB+ C. difficile prevalent area.
Shin BM; Lee EJ; Kuak EY; Yoo SJ
Anaerobe; 2009 Dec; 15(6):266-9. PubMed ID: 19772927
[TBL] [Abstract][Full Text] [Related]
29. A DNA vaccine targeting TcdA and TcdB induces protective immunity against Clostridium difficile.
Zhang BZ; Cai J; Yu B; Hua Y; Lau CC; Kao RY; Sze KH; Yuen KY; Huang JD
BMC Infect Dis; 2016 Oct; 16(1):596. PubMed ID: 27770789
[TBL] [Abstract][Full Text] [Related]
30. Human α-Defensin-6 Neutralizes
Barthold L; Heber S; Schmidt CQ; Gradl M; Weidinger G; Barth H; Fischer S
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562899
[TBL] [Abstract][Full Text] [Related]
31. Toward a structural understanding of Clostridium difficile toxins A and B.
Pruitt RN; Lacy DB
Front Cell Infect Microbiol; 2012; 2():28. PubMed ID: 22919620
[TBL] [Abstract][Full Text] [Related]
32. Functional defects in
Gupta P; Zhang Z; Sugiman-Marangos SN; Tam J; Raman S; Julien JP; Kroh HK; Lacy DB; Murgolo N; Bekkari K; Therien AG; Hernandez LD; Melnyk RA
J Biol Chem; 2017 Oct; 292(42):17290-17301. PubMed ID: 28842504
[No Abstract] [Full Text] [Related]
33. Processing of Clostridium difficile toxins.
Giesemann T; Egerer M; Jank T; Aktories K
J Med Microbiol; 2008 Jun; 57(Pt 6):690-696. PubMed ID: 18480324
[TBL] [Abstract][Full Text] [Related]
34. Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production.
Merrigan M; Venugopal A; Mallozzi M; Roxas B; Viswanathan VK; Johnson S; Gerding DN; Vedantam G
J Bacteriol; 2010 Oct; 192(19):4904-11. PubMed ID: 20675495
[TBL] [Abstract][Full Text] [Related]
35. Structural determinants of Clostridium difficile toxin A glucosyltransferase activity.
Pruitt RN; Chumbler NM; Rutherford SA; Farrow MA; Friedman DB; Spiller B; Lacy DB
J Biol Chem; 2012 Mar; 287(11):8013-20. PubMed ID: 22267739
[TBL] [Abstract][Full Text] [Related]
36. Binding of Clostridium difficile toxins to human milk oligosaccharides.
El-Hawiet A; Kitova EN; Kitov PI; Eugenio L; Ng KK; Mulvey GL; Dingle TC; Szpacenko A; Armstrong GD; Klassen JS
Glycobiology; 2011 Sep; 21(9):1217-27. PubMed ID: 21610194
[TBL] [Abstract][Full Text] [Related]
37. Effective Sequestration of Clostridium difficile Protein Toxins by Calcium Aluminosilicate.
Sturino JM; Pokusaeva K; Carpenter R
Antimicrob Agents Chemother; 2015 Dec; 59(12):7178-83. PubMed ID: 26149988
[TBL] [Abstract][Full Text] [Related]
38. Haemorrhagic toxin and lethal toxin from Clostridium sordellii strain vpi9048: molecular characterization and comparative analysis of substrate specificity of the large clostridial glucosylating toxins.
Genth H; Pauillac S; Schelle I; Bouvet P; Bouchier C; Varela-Chavez C; Just I; Popoff MR
Cell Microbiol; 2014 Nov; 16(11):1706-21. PubMed ID: 24905543
[TBL] [Abstract][Full Text] [Related]
39. The role of purified Clostridium difficile glucosylating toxins in disease pathogenesis utilizing a murine cecum injection model.
Zhang Y; Yang Z; Gao S; Hamza T; Yfantis HG; Lipsky M; Feng H
Anaerobe; 2017 Dec; 48():249-256. PubMed ID: 29031928
[TBL] [Abstract][Full Text] [Related]
40. New multiplex PCR method for the detection of Clostridium difficile toxin A (tcdA) and toxin B (tcdB) and the binary toxin (cdtA/cdtB) genes applied to a Danish strain collection.
Persson S; Torpdahl M; Olsen KE
Clin Microbiol Infect; 2008 Nov; 14(11):1057-64. PubMed ID: 19040478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
